Healthcare New Highs: China Cord Blood Corporation (NYSE:CO), Corcept Therapeutics (NASDAQ:CORT), Nordion (NYSE:NDZ), Vision-Sciences (NASDAQ:VSCI)

Stocks Almost Family and Chemed hold a Zacks Rank #1(Strong Buy) and China Cord Blood Corporation (NYSE:CO) holds a Zacks Rank #2 (Buy). With favorable Zacks Ranks, these stocks may be better selections at this time. China Cord Blood Corporation (NYSE:CO) stock performance was 3.26% in last session and finished the day at $4.44. Traded volume was 777.52K shares in the last session and the average volume of the stock remained 99.99K shares. The beta of the stock remained 0.96. China Cord Blood Corporation (NYSE:CO) insider ownership is 92.73%.

Corcept Therapeutics Incorporated (NASDAQ:CORT) Director Longitude Venture Partners L.P sold 250,000 shares of the company’s stock in a transaction that occurred on Friday, March 7th. Corcept Therapeutics Incorporated (NASDAQ:CORT) rose 3.16 percent to $4.08 Friday on volume of 812,543.00million shares. The intra-day range of the stock was $3.92 to $4.19. Corcept Therapeutics Incorporated (NASDAQ:CORT) has a market capitalization of $407.24million.

Nordion Inc. (USA) (NYSE:NDZ), a leading provider of products and services to the global health science market, today reported results for the first quarter of fiscal 2014. The Company generated $70.8 million in revenue for the first quarter of fiscal 2014, an increase of $17.2 million, or 32%, from revenue of $53.7 million for the same period in fiscal 2013. Nordion Inc (USA) (NYSE:NDZ)’s stock on Mar 7, 2014 reported a increase of 0.70% to the closing price of $10.14. Its fifty two weeks range is $6.43-$11.00. The total market capitalization recorded $627.76million. The overall volume in the last trading session was 766,819.00million shares. In its share capital, NDZ has 61.91million outstanding shares.

Vision-Sciences Inc. (NASDAQ:VSCI)’ EndoSheath Technology Provides Guaranteed Sterility Patient Safety Awareness Week, March 2 – 8, is dedicated to heightening awareness to a variety of ways that patients can be more involved in their health care. On Friday, shares of Vision-Sciences, Inc. (NASDAQ:VSCI) dropped -2.42% to close the day at $1.61. Company return on investment (ROI) is -114.10% and its monthly performance is recorded as 26.77%. Vision-Sciences, Inc. (NASDAQ:VSCI) quarterly revenue growth is 34.17%.